Biolargo Stock Price, News & Analysis

BioLargo, Inc. (OTCQB:BLGO) announced substantial financial progress in its Annual Report filed on March 31, 2023, revealing a 132% increase in revenues to $5.88 million for the year ended December 31, 2022. The net loss decreased by 26% to $5.13 million. Key highlights included significant revenue growth from the Pooph product and advancements in the PFAS treatment sector, with the company showcasing its capability to meet EPA standards for water contamination. Furthermore, BioLargo acquired IP rights to a sodium-sulfur battery technology, promising innovations in energy storage. The company will hold a public investor webcast on April 3, 2023, to discuss these developments.

BioLargo, Inc. (OTCQB:BLGO) will hold an investor webcast and conference call on April 3, 2023, at 1:30 pm Pacific / 4:30 pm Eastern to review its financial results for the fiscal year ending December 31, 2022. The public event will discuss recent milestones and include a Q&A session. Interested parties can register via the webcast link and will have access to a replay until April 17, 2023. BioLargo focuses on sustainable cleantech solutions addressing PFAS contamination and advanced water treatment. A replay of the webcast will be available for 90 days on their Investor Relations website.

BioLargo, Inc. (OTCQB:BLGO) announced its acquisition of proprietary sodium-sulfur battery technology, aimed at addressing the growing global demand for renewable energy and energy storage solutions. The newly formed subsidiary, BioLargo Energy Technologies, Inc. (BETI), will spearhead the manufacturing and commercialization of this technology, which offers enhanced safety, sustainability, and performance compared to lithium-ion batteries. The sodium-sulfur batteries have a longer lifespan, are immune to degradation, and operate effectively in stationary applications. This strategic move aligns with BioLargo’s focus on the water-energy nexus, promising significant long-term benefits for shareholders.

BioLargo, Inc. (OTCQB:BLGO) reported record-setting revenue growth for Q1 2023, surpassing previous quarterly figures. Driven by significant sales of the Pooph pet-odor control product through Ikigai Marketing Works, the company expects over 50% revenue growth compared to Q4 2022, marking the seventh consecutive quarter of growth. Preliminary Q1 2023 revenues are projected to exceed four times those of Q1 2022. While the company is not yet profitable, net losses are decreasing. An earnings conference call is scheduled for April 3, 2023, and the 2022 financial statements are under audit, with a filing expected by the end of March.

BioLargo, Inc. (OTCQB:BLGO) announced that its Aqueous Electrostatic Concentrator (AEC) technology can treat water to meet the EPA's proposed drinking water standards for PFAS, specifically PFOA and PFOS. The Biden-Harris administration proposed national drinking water regulations on March 14, 2023, targeting six PFAS chemicals with strict limits, including four parts per trillion for PFOA and PFOS. The AEC has demonstrated effectiveness in reducing PFAS levels in multiple studies. This regulatory change may increase demand for BioLargo's solutions as municipalities seek to comply with the new standards, which prioritize reducing contamination in drinking water.

BioLargo, Inc. (OTCQB:BLGO) announced the appointment of Nicholas Valeriani and Linda Park to its subsidiary Clyra Medical Technologies' board of directors. Valeriani brings 34 years of experience from Johnson & Johnson and holds multiple board positions, while Park has over 20 years of corporate governance experience with Edwards Lifesciences and Western Digital. The board expects their expertise will accelerate the commercialization of Clyra's innovative medical products, including BioClynse, an FDA 510(k)-cleared wound irrigation product. The leadership change aims to bolster strategic growth and operational efficiency for the company.

BioLargo, Inc. (OTCQB:BLGO) will feature CEO Dennis Calvert in a virtual fireside chat on January 25, 2023, at 12 PM ET via the Paltalk platform. This event is part of ClearThink IR's initiative, aimed at providing investors insights into emerging micro-cap companies. Attendees can engage directly in a Q&A session following the discussion. BioLargo focuses on developing sustainable cleantech and environmental engineering solutions addressing critical issues such as PFAS contamination and air quality improvement. For details on joining the event, visit here.

BioLargo (OTCQB:BLGO) reported a preliminary revenue of over $5.75 million for 2022, reflecting a remarkable 125% growth compared to 2021. CEO Dennis P. Calvert stated this success stems from a broad portfolio of sustainable technologies. The company anticipates continued growth in 2023, driven by its PFAS removal water treatment systems and other engineering projects. BioLargo is also expanding its network of channel partners in the U.S. and Canada, enhancing its market presence in the environmental technology sector.

BioLargo, Inc. (OTCQB:BLGO) announced the retail launch of its pet odor remover, Pooph, at over 600 Walmart locations across the United States. This marks the first step in a planned national distribution. According to Ikigai Marketing Works, the product's sales have exceeded expectations, with a strong marketing strategy highlighting its effective odor elimination. BioLargo continues to support Ikigai in expanding brand awareness. The company is recognized for its innovative cleantech solutions and extensive patent portfolio.